ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,168,732 | -2.6% | 2,438,052 | +10.4% | 0.02% | +4.8% |
| Q2 2023 | $67,901,176 | +26.9% | 2,208,887 | +48.7% | 0.02% | +16.7% |
| Q1 2023 | $53,520,274 | -2.4% | 1,485,436 | +7.1% | 0.02% | -5.3% |
| Q4 2022 | $54,820,000 | -0.7% | 1,387,148 | +0.9% | 0.02% | -5.0% |
| Q3 2022 | $55,216,000 | +1.8% | 1,374,241 | +6.6% | 0.02% | +5.3% |
| Q2 2022 | $54,220,000 | +7.7% | 1,289,699 | -0.2% | 0.02% | +26.7% |
| Q1 2022 | $50,331,000 | -2.9% | 1,292,117 | -0.7% | 0.02% | +7.1% |
| Q4 2021 | $51,819,000 | +11.0% | 1,300,671 | +0.7% | 0.01% | -6.7% |
| Q3 2021 | $46,702,000 | -15.7% | 1,292,261 | -4.4% | 0.02% | -11.8% |
| Q2 2021 | $55,427,000 | +0.5% | 1,352,176 | +7.0% | 0.02% | -5.6% |
| Q1 2021 | $55,153,000 | +39.0% | 1,263,884 | +59.4% | 0.02% | +28.6% |
| Q4 2020 | $39,672,000 | +51.9% | 792,683 | +27.7% | 0.01% | +27.3% |
| Q3 2020 | $26,115,000 | -62.3% | 620,718 | -56.5% | 0.01% | -63.3% |
| Q2 2020 | $69,201,000 | – | 1,425,370 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |